BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) received a listing approval notice from the China Securities Regulatory Commission (CSRC) on Monday, a necessary step before it can make an overseas…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
FAST NEWS: CMS Holdings Profit Rises as It Explores Medical Aesthetics
The latest: Drug maker China Medical System Holdings Ltd. (CMS Holdings) (0867.HK) on Wednesday evening said its net profit rose 19.2% last year to 3.02 billion yuan ($474 million), and…
FAST NEWS: 3SBio Sees Profit Doubling on Surging Revenues
The latest: 3SBio Inc. (1530.HK) released a positive profit forecast on Monday evening, estimating its net profit rose 100% to 120% for 2021, while its profit attributable to equity shareholders…
RELATED ARTICLES
-
Ascentage Pharma soars on deal with cancer drug competitor
6855.HK - IPO tea party set to resume with Guming’s regulatory nod from China?
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
-
Yeahka braces investors for bad first half while trying to depict a rosy future
9923.HK
- Mao Geping’s Hong Kong IPO gets lift from regulatory nod
- WeRide drives into Uber partnership, as U.S. listing plan idles
